288 related articles for article (PubMed ID: 36222320)
21. Omalizumab in children and adolescents with chronic spontaneous urticaria: Case series and review of the literature.
Passanisi S; Arasi S; Caminiti L; Crisafulli G; Salzano G; Pajno GB
Dermatol Ther; 2020 Jul; 33(4):e13489. PubMed ID: 32358910
[TBL] [Abstract][Full Text] [Related]
22. Prevalence, Management, and Anaphylaxis Risk of Cold Urticaria: A Systematic Review and Meta-Analysis.
Prosty C; Gabrielli S; Le M; Ensina LF; Zhang X; Netchiporouk E; Ben-Shoshan M
J Allergy Clin Immunol Pract; 2022 Feb; 10(2):586-596.e4. PubMed ID: 34673287
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
Maurer M; Ensina LF; Gimenez-Arnau AM; Sussman G; Hide M; Saini S; Grattan C; Fomina D; Rigopoulos D; Berard F; Canonica GW; Rockmann H; Irani C; Szepietowski JC; Leflein J; Bernstein JA; Peter JG; Kulthanan K; Godse K; Ardusso L; Ukhanova O; Staubach P; Sinclair R; Gogate S; Thomsen SF; Tanus T; Ye YM; Burciu A; Barve A; Modi D; Scosyrev E; Hua E; Letzelter K; Varanasi V; Patekar M; Severin T;
Lancet; 2024 Jan; 403(10422):147-159. PubMed ID: 38008109
[TBL] [Abstract][Full Text] [Related]
24. Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety.
Giménez-Arnau AM
Expert Opin Biol Ther; 2017 Mar; 17(3):375-385. PubMed ID: 28125304
[TBL] [Abstract][Full Text] [Related]
25. Are antihistamines still used during omalizumab treatment for chronic spontaneous urticaria?
Melé-Ninot G; Serra-Baldrich E; Spertino J; Guilarte M; Ribó González P; Lleonart-Bellfill R; Figueras-Nart I; Bonfill-Ortí M; Depreux N; Sala-Cunill A; Bielsa-Marsol I; Baliu-Piqué C; Sanmartín-Novell V; Garcia-Navarro X; Expósito-Serrano V; Garnica-Velandia D; Diaz-Sarrió MC; Gómez-Armayones S; Gich Saladich I; Giménez-Arnau A
Eur J Dermatol; 2022 Sep; 32(5):629-631. PubMed ID: 36468733
[TBL] [Abstract][Full Text] [Related]
26. Management problems in severe chronic inducible urticaria: Two case reports.
Bumbăcea RS; Deaconu CG; Berghea EC
Exp Ther Med; 2019 Aug; 18(2):960-963. PubMed ID: 31384330
[TBL] [Abstract][Full Text] [Related]
27. Clinical and laboratory parameters associated with treatment response to third-line therapies in chronic refractory urticaria: A real world study from northern India.
Mehta H; Bishnoi A; Parsad D; Kumaran MS
Dermatol Ther; 2022 Nov; 35(11):e15887. PubMed ID: 36181400
[TBL] [Abstract][Full Text] [Related]
28. Chronic urticaria treatment patterns and changes in quality of life: AWARE study 2-year results.
Maurer M; Giménez-Arnau A; Ensina LF; Chu CY; Jaumont X; Tassinari P
World Allergy Organ J; 2020 Sep; 13(9):100460. PubMed ID: 32983330
[TBL] [Abstract][Full Text] [Related]
29. The effect of COVID-19 on patients with chronic spontaneous urticaria treated with omalizumab and antihistamines: A cross-sectional, comparative study.
Bostan E; Zaid F; Karaduman A; Dogan S; Gulseren D; Yalici-Armagan B; Akdogan N; Ersoy-Evans S; Elcin G
J Cosmet Dermatol; 2021 Nov; 20(11):3369-3375. PubMed ID: 34599630
[TBL] [Abstract][Full Text] [Related]
30. Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort study.
Salman A; Ergun T; Gimenez-Arnau AM
J Dermatolog Treat; 2020 Mar; 31(2):204-209. PubMed ID: 30821591
[No Abstract] [Full Text] [Related]
31. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion.
Vestergaard C; Toubi E; Maurer M; Triggiani M; Ballmer-Weber B; Marsland A; Ferrer M; Knulst A; Giménez-Arnau A
Eur J Dermatol; 2017 Feb; 27(1):10-19. PubMed ID: 27882879
[TBL] [Abstract][Full Text] [Related]
32. The efficacy of omalizumab treatment in chronic spontaneous urticaria is associated with basophil phenotypes.
Johal KJ; Chichester KL; Oliver ET; Devine KC; Bieneman AP; Schroeder JT; MacGlashan DW; Saini SS
J Allergy Clin Immunol; 2021 Jun; 147(6):2271-2280.e8. PubMed ID: 33713769
[TBL] [Abstract][Full Text] [Related]
33. An observational study on the efficacy of single injection of omalizumab in the treatment of chronic spontaneous urticaria.
Lal Vijayalal S; Arora S; Dabas R; Janney MS; Jankal Basavarajappa S; Das NM
Dermatol Ther; 2020 Nov; 33(6):e14397. PubMed ID: 33040395
[TBL] [Abstract][Full Text] [Related]
34. Sex differences in the efficacy of omalizumab in the treatment of chronic spontaneous urticaria.
Sirufo MM; Bassino EM; De Pietro F; Ginaldi L; De Martinis M
Int J Immunopathol Pharmacol; 2021; 35():20587384211065870. PubMed ID: 35170369
[TBL] [Abstract][Full Text] [Related]
35. Omalizumab for refractory chronic spontaneous urticaria during concurrent immunomodulatory therapy for multiple sclerosis.
Syrigos N; Grapsa D; Syrigou E
Eur Ann Allergy Clin Immunol; 2017 Nov; 49(6):286-287. PubMed ID: 29249139
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of as-needed antihistamines in chronic spontaneous urticaria patients under omalizumab treatment.
Türk M; Yılmaz İ; Nazik Bahçecioğlu S; Can P; Ertaş R; Kartal D; Çınar SL; Kocatürk E
Dermatol Ther; 2021 Jan; 34(1):e14543. PubMed ID: 33190334
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness and safety of Omalizumab in the treatment of chronic spontaneous urticaria: Systematic review and meta-analysis.
Rubini NPM; Ensina LFC; Silva EMK; Sano F; Solé D
Allergol Immunopathol (Madr); 2019; 47(6):515-522. PubMed ID: 31607407
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic Strategy According to Differences in Response to Omalizumab in Patients With Chronic Spontaneous Urticaria.
Giménez Arnau AM; Valero Santiago A; Bartra Tomás J; Jáuregui Presa I; Labrador Horrillo M; Miquel Miquel FJ; Ortiz de Frutos J; Sastre J; Silvestre Salvador JF; Ferrer Puga M
J Investig Allergol Clin Immunol; 2019; 29(5):338-348. PubMed ID: 30222111
[TBL] [Abstract][Full Text] [Related]
39. Hematologic parameters as biomarkers for antihistamine and omalizumab resistance in chronic spontaneous urticaria.
Magen E; Waitman DA; Kahan NR
Allergy Asthma Proc; 2021 Jan; 42(1):e17-e24. PubMed ID: 33404397
[No Abstract] [Full Text] [Related]
40. Omalizumab therapy for chronic spontaneous urticaria: the Israeli experience.
Rottem M; Segal R; Kivity S; Shamshines L; Graif Y; Shalit M; Kessel A; Panasoff J; Cohen S; Toubi E; Agmon-Levin N
Isr Med Assoc J; 2014 Aug; 16(8):487-90. PubMed ID: 25269339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
